source
- RNAi biotech ADARx raises $446 million in IPO, secures $89 million from AbbVieADARx Pharmaceuticals priced its initial public offering at $17 per share, selling more than 26 million shares to raise about $446.3 million. The company also received an additional $89 million th…
- FDA approves Mirum's Atebrioz for ultra-rare disease that hardens muscle and connective tissueThe U.S. Food and Drug Administration has granted approval for Mirum Pharmaceuticals' new therapy for an ultra-rare genetic disorder that causes muscle and connective tissue to turn into bone. The…